COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk has implemented a global hiring freeze covering job roles that are not ...

Novo Nordisk A/S said it has implemented a global hiring freeze as the Danish maker of weight-loss drugs seeks to cut costs ...

Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its ...

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk is to freeze hiring in an effort to control costs at the drug maker. The halt will apply across all markets and ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

It faces more than 1,800 lawsuits consolidated in federal court in Pennsylvania and new claims emerging weekly, according to ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...